Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND study

Joshua I. Barzilay, Peggy Gao, Lars Rydén, Helmut Schumacher, Jeffrey Probstfield, Patrick Commerford, Antonio Dans, Rafael Ferreira, M. Keltai, Ernesto Paolasso, Salim Yusuf, Koon Teo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE - Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS - Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS - During a median 56 months, 21.8% of participants treated with telmisartan and 22.4%of those on placebo developed diabetes (relative ratio 0.95 [95%CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. CONCLUSIONS - There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.

Original languageEnglish
Pages (from-to)1902-1907
Number of pages6
JournalDiabetes Care
Volume34
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Cardiovascular Diseases
Glucose Intolerance
Angiotensin Receptor Antagonists
Glucose
Fasting
Placebos
Angiotensin-Converting Enzyme Inhibitors
Research Design
telmisartan
Clinical Trials
Incidence

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Barzilay, J. I., Gao, P., Rydén, L., Schumacher, H., Probstfield, J., Commerford, P., ... Teo, K. (2011). Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND study. Diabetes Care, 34(9), 1902-1907. https://doi.org/10.2337/dc11-0545

Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes : The TRANSCEND study. / Barzilay, Joshua I.; Gao, Peggy; Rydén, Lars; Schumacher, Helmut; Probstfield, Jeffrey; Commerford, Patrick; Dans, Antonio; Ferreira, Rafael; Keltai, M.; Paolasso, Ernesto; Yusuf, Salim; Teo, Koon.

In: Diabetes Care, Vol. 34, No. 9, 09.2011, p. 1902-1907.

Research output: Contribution to journalArticle

Barzilay, JI, Gao, P, Rydén, L, Schumacher, H, Probstfield, J, Commerford, P, Dans, A, Ferreira, R, Keltai, M, Paolasso, E, Yusuf, S & Teo, K 2011, 'Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND study', Diabetes Care, vol. 34, no. 9, pp. 1902-1907. https://doi.org/10.2337/dc11-0545
Barzilay, Joshua I. ; Gao, Peggy ; Rydén, Lars ; Schumacher, Helmut ; Probstfield, Jeffrey ; Commerford, Patrick ; Dans, Antonio ; Ferreira, Rafael ; Keltai, M. ; Paolasso, Ernesto ; Yusuf, Salim ; Teo, Koon. / Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes : The TRANSCEND study. In: Diabetes Care. 2011 ; Vol. 34, No. 9. pp. 1902-1907.
@article{3a04c0bea10c4d0aa660e357ea437598,
title = "Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND study",
abstract = "OBJECTIVE - Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS - Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61{\%} male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS - During a median 56 months, 21.8{\%} of participants treated with telmisartan and 22.4{\%}of those on placebo developed diabetes (relative ratio 0.95 [95{\%}CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5{\%}) or to progress to incident diabetes (20.1 vs. 21.1{\%}; P = 0.59) on telmisartan or placebo. CONCLUSIONS - There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.",
author = "Barzilay, {Joshua I.} and Peggy Gao and Lars Ryd{\'e}n and Helmut Schumacher and Jeffrey Probstfield and Patrick Commerford and Antonio Dans and Rafael Ferreira and M. Keltai and Ernesto Paolasso and Salim Yusuf and Koon Teo",
year = "2011",
month = "9",
doi = "10.2337/dc11-0545",
language = "English",
volume = "34",
pages = "1902--1907",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes

T2 - The TRANSCEND study

AU - Barzilay, Joshua I.

AU - Gao, Peggy

AU - Rydén, Lars

AU - Schumacher, Helmut

AU - Probstfield, Jeffrey

AU - Commerford, Patrick

AU - Dans, Antonio

AU - Ferreira, Rafael

AU - Keltai, M.

AU - Paolasso, Ernesto

AU - Yusuf, Salim

AU - Teo, Koon

PY - 2011/9

Y1 - 2011/9

N2 - OBJECTIVE - Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS - Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS - During a median 56 months, 21.8% of participants treated with telmisartan and 22.4%of those on placebo developed diabetes (relative ratio 0.95 [95%CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. CONCLUSIONS - There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.

AB - OBJECTIVE - Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS - Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS - During a median 56 months, 21.8% of participants treated with telmisartan and 22.4%of those on placebo developed diabetes (relative ratio 0.95 [95%CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. CONCLUSIONS - There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84856784851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856784851&partnerID=8YFLogxK

U2 - 10.2337/dc11-0545

DO - 10.2337/dc11-0545

M3 - Article

C2 - 21788624

AN - SCOPUS:84856784851

VL - 34

SP - 1902

EP - 1907

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -